JP5932970B2 - 末梢免疫機能を調節するための方法及び組成物 - Google Patents

末梢免疫機能を調節するための方法及び組成物 Download PDF

Info

Publication number
JP5932970B2
JP5932970B2 JP2014504019A JP2014504019A JP5932970B2 JP 5932970 B2 JP5932970 B2 JP 5932970B2 JP 2014504019 A JP2014504019 A JP 2014504019A JP 2014504019 A JP2014504019 A JP 2014504019A JP 5932970 B2 JP5932970 B2 JP 5932970B2
Authority
JP
Japan
Prior art keywords
cells
peripheral
composition
cell
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014504019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510153A (ja
Inventor
ダオ モー
ダオ モー
ケース ケイシー
ケース ケイシー
Original Assignee
サンバイオ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンバイオ，インコーポレイティド filed Critical サンバイオ，インコーポレイティド
Publication of JP2014510153A publication Critical patent/JP2014510153A/ja
Application granted granted Critical
Publication of JP5932970B2 publication Critical patent/JP5932970B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
JP2014504019A 2011-04-06 2012-04-06 末梢免疫機能を調節するための方法及び組成物 Active JP5932970B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161516637P 2011-04-06 2011-04-06
US61/516,637 2011-04-06
US201161541248P 2011-09-30 2011-09-30
US61/541,248 2011-09-30
PCT/US2012/032504 WO2012154344A1 (en) 2011-04-06 2012-04-06 Methods and compositions for modulating peripheral immune function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016089159A Division JP6134032B2 (ja) 2011-04-06 2016-04-27 末梢免疫機能を調節するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2014510153A JP2014510153A (ja) 2014-04-24
JP5932970B2 true JP5932970B2 (ja) 2016-06-08

Family

ID=47139503

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2014504019A Active JP5932970B2 (ja) 2011-04-06 2012-04-06 末梢免疫機能を調節するための方法及び組成物
JP2016089159A Active JP6134032B2 (ja) 2011-04-06 2016-04-27 末梢免疫機能を調節するための方法及び組成物
JP2017083713A Active JP6392926B2 (ja) 2011-04-06 2017-04-20 末梢免疫機能を調節するための方法及び組成物
JP2018153539A Active JP6981934B2 (ja) 2011-04-06 2018-08-17 末梢免疫機能を調節するための方法及び組成物
JP2020150411A Active JP7267976B2 (ja) 2011-04-06 2020-09-08 末梢免疫機能を調節するための方法及び組成物
JP2023012476A Active JP7631387B2 (ja) 2011-04-06 2023-01-31 末梢免疫機能を調節するための方法及び組成物
JP2025017444A Pending JP2025069383A (ja) 2011-04-06 2025-02-05 末梢免疫機能を調節するための方法及び組成物

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2016089159A Active JP6134032B2 (ja) 2011-04-06 2016-04-27 末梢免疫機能を調節するための方法及び組成物
JP2017083713A Active JP6392926B2 (ja) 2011-04-06 2017-04-20 末梢免疫機能を調節するための方法及び組成物
JP2018153539A Active JP6981934B2 (ja) 2011-04-06 2018-08-17 末梢免疫機能を調節するための方法及び組成物
JP2020150411A Active JP7267976B2 (ja) 2011-04-06 2020-09-08 末梢免疫機能を調節するための方法及び組成物
JP2023012476A Active JP7631387B2 (ja) 2011-04-06 2023-01-31 末梢免疫機能を調節するための方法及び組成物
JP2025017444A Pending JP2025069383A (ja) 2011-04-06 2025-02-05 末梢免疫機能を調節するための方法及び組成物

Country Status (6)

Country Link
US (6) US8785190B2 (https=)
EP (1) EP2694080B1 (https=)
JP (7) JP5932970B2 (https=)
CN (2) CN106692193B (https=)
CA (1) CA2832356C (https=)
WO (1) WO2012154344A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017149759A (ja) * 2011-04-06 2017-08-31 サンバイオ，インコーポレイティド 末梢免疫機能を調節するための方法及び組成物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112386681A (zh) 2012-01-27 2021-02-23 桑比欧公司 用于调节血管生成和血管发生的方法和组合物
CN104519891B (zh) 2012-05-16 2019-03-22 桑比欧公司 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
WO2014058464A1 (en) 2012-10-09 2014-04-17 Sanbio, Inc. Methods and compositions for treatment of retinal degeneration
US20160008401A1 (en) * 2013-03-01 2016-01-14 Apceth Gmbh & Co. Kg Protection of the vascular endothelium from immunologically mediated cytotoxic reactions with human cd34-negative progenitor cells
EP2972368B1 (en) * 2013-03-15 2019-07-24 TiGenix, S.A.U. Lymphocyte biomarkers for determining the clinical response to cell therapy
US20160095885A1 (en) 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
CN105985928A (zh) * 2015-02-10 2016-10-05 睿尔（天津）生物科技有限公司 一种增强间充质干细胞免疫调节能力的预处理培养方法
JP7237449B2 (ja) * 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
CN106148276A (zh) * 2015-04-16 2016-11-23 中国科学院上海生命科学研究院 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
CN107847657A (zh) * 2015-06-15 2018-03-27 生命治疗有限公司 用于诱导抗炎反应的组合物和方法
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
WO2017143219A2 (en) * 2016-02-18 2017-08-24 Viera Bioscience, Inc. Stimulation of therapeutic angiogenesis by t regulatory cells
EP3463482B1 (en) 2016-06-07 2021-10-06 The Brigham and Women's Hospital, Inc. Methods relating to t peripheral helper cells in autoantibody-associated conditions
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
WO2018125829A1 (en) 2016-12-28 2018-07-05 Sanbio, Inc. Cell delivery system and methods of operation thereof
CA3287539A1 (en) 2017-06-21 2026-03-02 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
EP4046642A4 (en) 2019-10-17 2022-12-21 TERUMO Kabushiki Kaisha CELL CULTURE FOR THE TREATMENT OF INFLAMMATORY DISEASES
CN111979186B (zh) * 2020-08-21 2022-04-08 遵义医科大学附属医院 一种快速高效体外扩增人间充质干细胞的方法及应用
CN116376828B (zh) * 2023-06-02 2023-08-11 成都云测医学生物技术有限公司 一种诱导CD4+T细胞生成Treg细胞的方法及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5932970Y2 (ja) 1979-09-29 1984-09-14 トキナ−光学株式会社 ズ−ム式交換レンズにおける焦点距離の表示装置
JPS5993639U (ja) 1982-12-11 1984-06-25 愛知電機株式会社 撹拌装置における内容物の自動排出，投入装置
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
CZ295997B6 (cs) * 1996-11-07 2005-12-14 Lorantis Limited Farmaceutický prostředek s obsahem ligandu Notch a způsob tvorby T-buněk
US6280718B1 (en) 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
WO2003011317A1 (en) * 2001-07-25 2003-02-13 Lorantis Limited Modulators of notch signalling for use in immunotherapy
US6887706B2 (en) 2001-10-03 2005-05-03 Wisconsin Alumni Research Foundation Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells
DK1479767T3 (da) 2002-02-06 2013-11-25 Sanbio Inc Fremgangsmåde til differentiering/inducering af stromaceller fra knoglemarv til nerveceller ved overføring af Notch-gen
EP1737950B9 (en) 2004-04-12 2012-04-18 Sanbio, Inc. Cells exhibiting neuronal progenitor cell characteristics
PT1855700E (pt) 2005-03-07 2013-12-10 Sanbio Inc Utilização de materiais para tratamento de lesões do sistema nervoso central
WO2008102460A1 (en) 2007-02-23 2008-08-28 Sanbio Inc. Transplantation of bone marrow stromal cell-induced neural stem cells for promoting fuctional recovery after spinal cord injury
US8945919B2 (en) * 2007-08-15 2015-02-03 San Bio, Inc. Methods and composition for treating neural degeneration
EP2215216B1 (en) 2007-12-03 2018-05-30 SanBio, Inc. Extracellular matrix from pluripotent cells
ES2594229T3 (es) * 2008-04-30 2016-12-16 Sanbio, Inc. Células de regeneración nerviosa con alteraciones en la metilación del ADN
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
US8518397B2 (en) * 2009-08-14 2013-08-27 Case Western Reserve University Notch induced natural killer cell generation and therapeutic uses
EP2694080B1 (en) * 2011-04-06 2018-03-14 SanBio, Inc. Methods and compositions for modulating peripheral immune function
US20120263681A1 (en) * 2011-04-12 2012-10-18 Fujifilm Corporation Composition comprising cell and biocompatible polymer

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017149759A (ja) * 2011-04-06 2017-08-31 サンバイオ，インコーポレイティド 末梢免疫機能を調節するための方法及び組成物
JP2019006790A (ja) * 2011-04-06 2019-01-17 サンバイオ，インコーポレイティド 末梢免疫機能を調節するための方法及び組成物
JP2021001180A (ja) * 2011-04-06 2021-01-07 サンバイオ，インコーポレイティド 末梢免疫機能を調節するための方法及び組成物
JP2023052777A (ja) * 2011-04-06 2023-04-12 サンバイオ，インコーポレイティド 末梢免疫機能を調節するための方法及び組成物
JP7267976B2 (ja) 2011-04-06 2023-05-02 サンバイオ，インコーポレイティド 末梢免疫機能を調節するための方法及び組成物
US11903972B2 (en) 2011-04-06 2024-02-20 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
JP7631387B2 (ja) 2011-04-06 2025-02-18 サンバイオ，インコーポレイティド 末梢免疫機能を調節するための方法及び組成物
JP2025069383A (ja) * 2011-04-06 2025-04-30 サンバイオ，インコーポレイティド 末梢免疫機能を調節するための方法及び組成物

Also Published As

Publication number Publication date
EP2694080A1 (en) 2014-02-12
CN106692193A (zh) 2017-05-24
JP2019006790A (ja) 2019-01-17
JP6392926B2 (ja) 2018-09-19
JP2016135817A (ja) 2016-07-28
USRE46382E1 (en) 2017-05-02
US11903972B2 (en) 2024-02-20
CA2832356A1 (en) 2012-11-15
JP2017149759A (ja) 2017-08-31
US8785190B2 (en) 2014-07-22
CN106692193B (zh) 2021-01-05
JP7267976B2 (ja) 2023-05-02
JP2025069383A (ja) 2025-04-30
US20200113944A1 (en) 2020-04-16
US20170232042A1 (en) 2017-08-17
EP2694080A4 (en) 2014-09-03
EP2694080B1 (en) 2018-03-14
JP7631387B2 (ja) 2025-02-18
US20140286918A1 (en) 2014-09-25
JP6981934B2 (ja) 2021-12-17
WO2012154344A1 (en) 2012-11-15
US9655927B2 (en) 2017-05-23
JP2014510153A (ja) 2014-04-24
CN103547275B (zh) 2016-12-28
US20240139255A1 (en) 2024-05-02
JP6134032B2 (ja) 2017-05-24
JP2021001180A (ja) 2021-01-07
CN103547275A (zh) 2014-01-29
US20130095084A1 (en) 2013-04-18
US10543234B2 (en) 2020-01-28
JP2023052777A (ja) 2023-04-12
CA2832356C (en) 2017-12-19

Similar Documents

Publication Publication Date Title
JP7631387B2 (ja) 末梢免疫機能を調節するための方法及び組成物
CN103079579B (zh) T细胞介导的免疫病症的治疗
AU2011274255A1 (en) Treatment of T-cell mediated immune disorders
HK1233517A (en) Methods and compositions for modulating peripheral immune function
HK1233517A1 (en) Methods and compositions for modulating peripheral immune function
HK1233517B (zh) 用於调节外周免疫功能的方法和组合物
HK1191880A (en) Methods and compositions for modulating peripheral immune function
HK1191880B (en) Methods and compositions for modulating peripheral immune function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160428

R150 Certificate of patent or registration of utility model

Ref document number: 5932970

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250